Krebs Biochemicals & Industries Limited has filed its mandatory compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The certificate was submitted to stock exchanges on April 7, 2026, fulfilling the company's regulatory obligations under the SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Filing

The company submitted the required documentation to both major Indian stock exchanges where its shares are listed. The filing includes certificates from KFIN Technologies Limited, which serves as the company's Registrar and Share Transfer Agent.

Certificate Verification

KFIN Technologies Limited, acting as the Registrar to an Issue and Share Transfer Agent, provided separate certificates to both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). These certificates confirm that details of securities dematerialized and rematerialized during the quarter have been furnished to all stock exchanges where the company's shares are listed.

The certificates were issued on April 1, 2026, and signed by Praveen Chaturvedi, Senior Vice President at KFIN Technologies Limited. Both depositories received identical confirmations regarding the company's compliance with the regulatory requirements.

Company Authorization

The submission was authorized by Rakesh R Kalbate, Company Secretary & Compliance Officer of Krebs Biochemicals & Industries Limited. The filing was digitally signed and includes the company's registered address at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District, Andhra Pradesh.

KFIN Technologies Role

KFIN Technologies Limited operates from multiple locations, with its operations centre in Hyderabad's Financial District and registered office in Mumbai. The company serves as the registrar and share transfer agent, ensuring compliance with SEBI regulations for securities dematerialization and rematerialization processes.

This quarterly filing represents part of the standard regulatory framework that listed companies must follow to maintain transparency in their securities transactions and depositories operations.

Krebs Biochemicals & Industries Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, revealing continued operational challenges amid regulatory constraints. The company reported a net loss of ₹312.65 lacs for Q3FY26, representing an improvement from the ₹773.89 lacs loss recorded in the corresponding quarter of the previous year.

Financial Performance Overview

The company's revenue from operations declined significantly by 36.55% year-on-year to ₹727.42 lacs in Q3FY26 from ₹1,146.72 lacs in Q3FY24. However, on a sequential basis, the company showed improvement with revenue increasing by 74.55% from ₹416.74 lacs in Q2FY26. This substantial revenue decline reflects the ongoing impact of operational disruptions on the company's business activities.

Expense Analysis

Despite the revenue decline, the company managed to control certain expense categories. Employee benefits expenses decreased to ₹269.25 lacs in Q3FY26 from ₹450.42 lacs in Q3FY24. However, finance costs increased to ₹179.29 lacs from ₹155.67 lacs in the same period, indicating higher borrowing costs. Other expenses showed significant reduction to ₹428.32 lacs from ₹1,036.91 lacs in Q3FY24.

Nine-Month Performance

For the nine-month period ended December 31, 2025, Krebs Biochemicals reported revenue from operations of ₹1,692.25 lacs compared to ₹3,721.14 lacs in the corresponding period of FY24, marking a decline of 54.52%. The net loss for the nine-month period was ₹1,459.35 lacs against ₹1,867.09 lacs in the previous year.

Operational Challenges

A critical factor affecting the company's performance is the continued closure of its Vizag manufacturing unit. The operations remain suspended pursuant to an order dated February 7, 2025, passed by the Andhra Pradesh Pollution Control Board. This regulatory action has significantly impacted the company's production capabilities and overall financial performance.

Balance Sheet Position

As of December 31, 2025, the company's total assets stood at ₹16,591.40 lacs compared to ₹16,903.56 lacs as of March 31, 2025. The company reported negative equity of ₹16,083.25 lacs, reflecting accumulated losses over time. Non-current borrowings increased to ₹16,500.00 lacs from ₹16,125.00 lacs, while current borrowings rose to ₹5,647.24 lacs from ₹5,095.84 lacs.

Corporate Governance

The basic and diluted earnings per share for Q3FY26 stood at ₹-1.45 compared to ₹-3.59 for the corresponding quarter of the previous year. The paid-up equity share capital remained unchanged at ₹2,156.06 lacs with a face value of ₹10.00 per share. The company operates in a single business segment and does not have any subsidiary, associate, or joint venture companies as of December 31, 2025.

The financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 9, 2026. The Board meeting commenced at 12:00 Noon and concluded at 01:30 p.m.